Asciminib RMP Study

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

July 19, 2023

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions
Chronic Myeloid Leukemia
Interventions
OTHER

Asciminib

There is no treatment allocation. Asciminib will be prescribed by the physician as per locally approved label. No drug will be dispensed from Novartis

Trial Locations (14)

10408

RECRUITING

Novartis Investigative Site, Gyeonggi-do

11759

RECRUITING

Novartis Investigative Site, Uijeongbu-si

26426

RECRUITING

Novartis Investigative Site, Wŏnju

41944

RECRUITING

Novartis Investigative Site, Taegu

519763

RECRUITING

Novartis Investigative Site, Jeollanam

06591

RECRUITING

Novartis Investigative Site, Seoul

405 760

RECRUITING

Novartis Investigative Site, Incheon

614 735

RECRUITING

Novartis Investigative Site, Pusan

02841

RECRUITING

Novartis Investigative Site, Seoul

03080

RECRUITING

Novartis Investigative Site, Seoul

03722

RECRUITING

Novartis Investigative Site, Seoul

05505

RECRUITING

Novartis Investigative Site, Seoul

06351

RECRUITING

Novartis Investigative Site, Seoul

158-710

RECRUITING

Novartis Investigative Site, Seoul

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY